First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
First Tracks Biotherapeutics, a clinical-stage biotech company focused on antibody therapies for autoimmune and inflammatory diseases, officially launched as an independent public company on Nasdaq under the ticker TRAX. The company has a strong financial foundation with $180 million in cash and a two-year cash runway. Its pipeline features three d…